Core Viewpoint - Chinese companies seeking to list in Hong Kong must obtain a filing notice from the China Securities Regulatory Commission (CSRC) and submit this notice at least four business days before the listing hearing date at the Hong Kong Stock Exchange (HKEX) [1]. Group 1: CSRC Filing Requirements - The CSRC's International Department issued supplementary material requirements for 19 companies listed in Hong Kong during the week of December 22-26, 2025 [2]. - Companies such as Hai Lan Home, Proya, and Xunlong Technology are among those required to provide additional legal opinions and clarifications regarding their operations and shareholder structures [2][6][13]. Group 2: Specific Company Inquiries - Hai Lan Home must clarify the potential impact of its controlling shareholder's debt repayment ability on the company's control and provide details on its business operations related to internet data services [2][3]. - Xunlong Technology, the world's largest caviar company, is required to explain the tax situation of its recent share transfers and whether its fundraising involves overseas investments [6][10]. - Proya is asked to detail its fundraising purposes, data collection practices, and compliance with foreign investment regulations in the cultural and entertainment sectors [13][14]. Group 3: Compliance and Regulatory Issues - Companies must ensure compliance with foreign exchange management and investment regulations during their corporate structure setups and any potential mergers [16][22]. - There are inquiries regarding the existence of shareholding arrangements and employee stock ownership plans that may affect the companies' governance and control [3][18].

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry [2]. Core Insights - The cosmetics and medical beauty sector underperformed the market, with the Shenwan Beauty Care Index declining by 1.1% from December 19 to December 26, 2025, which is weaker than the market performance [4][5]. - Lin Qingxuan is set to lead the high-end domestic essence oil sector with its upcoming IPO on December 30, 2025, planning to issue 13.9665 million H shares. The company has shown significant growth, with revenue projected to increase from 690 million yuan in 2022 to 1.21 billion yuan in 2024, representing a compound annual growth rate (CAGR) of 32.7% [4][10]. - The report highlights the strong performance of Yiwang Yichuang (300792SZ) in the e-commerce agency sector, leveraging AI to enhance operational efficiency and revenue potential [11][12]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector's performance was weaker than the market, with specific indices showing declines: the Shenwan Cosmetics Index fell by 1.3%, and the Shenwan Personal Care Index decreased by 1.0% [4][5]. Key Company Developments - Lin Qingxuan's IPO is anticipated to bolster its market position, with a focus on high-end skincare products. The company has achieved a market share of 1.4% in the high-end skincare segment and ranks 10th in the anti-wrinkle product market with a 2.2% share [10]. - Yiwang Yichuang's business model is robust, with a comprehensive coverage of consumer goods categories and deep collaboration with Alibaba, positioning it well for future growth [11][12]. Market Trends - The report notes a recovery in the e-commerce agency sector, driven by increased demand for brand representation on platforms like Alibaba, with a notable rebound in traffic [12][13]. - The overall retail sales of cosmetics in China showed a growth of 4.8% year-on-year for the first 11 months of 2025, with November alone seeing a 6.1% increase, aided by promotional events [18][20]. Regulatory and Product Innovations - Jiangsu Chuangjian Medical Technology's collagen implant product received approval from NMPA, indicating ongoing innovation in the medical beauty sector [22]. - The report also mentions the investment by L'Oréal in a Chinese pharmaceutical company, marking a significant move into the skin health sector [25].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The retail industry is experiencing a transformation with a focus on emotional consumption and innovative product offerings, particularly in the jewelry and cosmetics sectors [6][33] - Companies like潮宏基 and毛戈平 are leveraging multi-channel strategies to enhance brand visibility and product sales, indicating a strong market presence [26][31] Summary by Sections Retail Market Overview - The retail index closed at 2462.73 points, with a weekly increase of 0.16%, underperforming the Shanghai Composite Index, which rose by 1.88% [5][15] - The retail sector has seen a year-to-date increase of 10.00%, lagging behind the Shanghai Composite Index's 18.26% rise [15][19] Company Highlights - **潮宏基**: Achieved a revenue of 62.37 billion yuan in the first three quarters of 2025, up 28.4% year-on-year, with a net profit of 3.17 billion yuan, reflecting a 0.3% increase [42] - **毛戈平**: Launched the "琉光赋活" skincare series, set to debut on January 1, 2026, focusing on high-end skincare needs [31] - **周大福**: Reported a revenue of 389.86 billion HKD for FY2026H1, a slight decrease of 1.1%, but with a net profit increase of 0.1% [39] Investment Themes - **Gold and Jewelry**: Focus on brands with differentiated product offerings and consumer insights, recommending潮宏基 and老铺黄金 as key players [6][33] - **Offline Retail**: Emphasis on companies adapting to market changes, with recommendations for永辉超市 and爱婴室 [6][33] - **Cosmetics**: Highlighting brands that innovate with emotional value and safe ingredients, recommending毛戈平 and珀莱雅 [6][34] - **Medical Aesthetics**: Targeting differentiated product manufacturers and expanding medical aesthetic chains, with recommendations for爱美客 and科笛-B [6][34]

来源：新浪证券 出品：新浪财经上市公司研究院 作者：喜乐 12月18日，林清轩启动港股全球发售，预计于12月30日上市。本次IPO采用定价发行，发行价为77.77港 元/股，基础发行股数约1397万股，绿鞋后发行股数约1606万股，对应发行规模约10.9-12.5亿元。作为 港股市场首个主打"本土高端护肤"定位的上市企业，林清轩的IPO不仅承载着自身的资本跃迁梦想，更 被视作观察资本市场对国货高端化价值判断的重要样本。其亮眼的业绩增长、独特的品牌定位与多元化 的资本支持，让这场上市备受瞩目，但与此同时，市场对其高端定位、竞争韧性及估值合理性的质疑也 从未停歇，这场资本盛宴背后的多重考验正逐步浮现。 深耕山茶花赛道 2025年上半年收入盈利近翻倍 林清轩自2012年起开展山茶花护肤品研究，开创"以油养肤"理念，2014年推出的首款山茶花精华油成为 核心产品。历经多年发展，林清轩旗下提供全系列高端护肤改善方案，包括精华油、面霜、爽肤水及乳 液、精华液、面膜及防晒霜，旨在支持自清洁及爽肤至保湿及针对性护肤的全套护肤流程。截至2025年 6月30日，林清轩提供230个SKU。 业绩层面，林清轩近年实现跨越式增长。20 ...

Core Viewpoint - The "beautiful economy" is thriving in Lishui's Liandu District, with significant developments in the beauty and health industry, including partnerships with major beauty brands and impressive industrial output figures [1][4]. Group 1: Industry Development - Liandu District has signed cooperation agreements with beauty giants Proya and Oushiman, positioning itself as a new hub for the beauty and health industry [4]. - The health industry in Liandu has seen a total industrial output value of 9.837 billion yuan from January to November this year, with expectations to exceed 10.88 billion yuan by 2024 [1][5]. - The district has attracted over 100 upstream and downstream enterprises in the beauty and health industry, forming a collaborative industrial structure led by companies like Naies and Mingye Technology [5]. Group 2: Strategic Initiatives - The local government has implemented several strategic plans, including the "Three-Year Action Plan for the Development of Traditional Chinese Medicine and Health Industry" and the "Development Plan for the Beautiful Health Industry" [7]. - Liandu is focusing on six main sectors: ecological beauty, fashion medical aesthetics, oral healthcare, modern traditional medicine, health tea and coffee, and pet products [7]. - The establishment of innovation centers and industry funds totaling 1 billion yuan aims to enhance project attraction and optimize the beauty and health industry chain [7][8]. Group 3: Future Goals - By 2030, the Liandu District aims to achieve an industrial output value of over 20 billion yuan in the beauty and health sector and cultivate nationally influential innovative enterprises [9]. - The district plans to build the "China Lishui Beautiful Health Port" as a central initiative to drive the development of beauty, health, and emotional economy sectors [9].

Group 1 - The China Securities Regulatory Commission (CSRC) issued supplementary material requirements for 19 companies, including Proya Cosmetics, which is required to clarify foreign investment access and other matters [1][2] - Proya Cosmetics has submitted its listing application to the Hong Kong Stock Exchange, with CICC and UBS as joint sponsors [1] - The CSRC requests Proya to clarify the use of raised funds, particularly regarding any overseas investments and compliance with relevant approval procedures [1][2] Group 2 - Proya's subsidiaries are involved in various businesses, including advertising, and the CSRC requires clarification on the compliance and operational status of these activities [2] - Proya is recognized as the fifth largest cosmetics group in China by retail sales in 2024, being the only domestic cosmetics group among the top five [2] - The company has maintained its position as the largest domestic cosmetics group in China for four consecutive years from 2021 to 2024 based on retail sales [2]

智通财经APP获悉，12月26日，中国证监会发布《境外发行上市备案补充材料要求(2025年12月22日— 2025年12月26日)》。中国证监会国际司共对19家企业出具补充材料要求，其中，要求珀莱雅 (603605.SH)补充说明关于外资准入等事项。据港交所10月30日披露，珀莱雅化妆品股份有限公司向港 交所主板提交上市申请书，中金公司、瑞银集团为其联席保荐人。 招股书显示，珀莱雅是一家中国本土多品牌美妆集团，致力于搭建国际一流的化妆品产业平台，为全球 消费者带来兼具科技与高品质的化妆品产品消费体验。公司建立了覆盖不同消费人群的多品牌、多品类 化妆品矩阵，已覆盖护肤、彩妆、个人护理等领域。 证监会请珀莱雅补充说明以下事项，请律师核查并出具明确的法律意见： 根据弗若斯特沙利文的资料，以2024年零售额计，在中国化妆品行业前五大集团中，公司位列第五，是 唯一一家中国本土化妆品集团。以零售额计，公司于2021年至2024年连续四年为中国最大的本土化妆品 集团。 三、发行人下属公司经营范围包含设计、制作、代理、发布广告等，请说明广告相关业务开展情况，是 否取得必要的资质许可。 四、关于外资准入：(1)发行人境内下属公 ...

Group 1 - The China Securities Regulatory Commission (CSRC) issued supplementary material requirements for 19 companies, including Proya Cosmetics Co., Ltd. (603605.SH), which is seeking to list on the Hong Kong Stock Exchange [1][2] - Proya is required to clarify the use of funds raised in the issuance, particularly regarding any overseas investments and compliance with relevant approval procedures [1] - The company must also provide details on its subsidiaries' operations related to apps and data collection, including the scale of user information collected and stored [1][2] Group 2 - Proya is a domestic multi-brand beauty group in China, aiming to build a world-class cosmetics industry platform and provide high-quality cosmetic products to global consumers [2] - The company has established a diverse portfolio covering skincare, makeup, and personal care, and ranks fifth among the top five cosmetic groups in China by retail sales, according to Frost & Sullivan [2] - Proya has been the largest domestic cosmetics group in China by retail sales for four consecutive years from 2021 to 2024 [2]

Core Viewpoint - The article discusses the journey of the Chinese cosmetics brand, Chando, founded by Zheng Chunying and his siblings, highlighting its growth, IPO preparations, and strategic investments from major players like L'Oréal and Himalaya International. Group 1: Company Background and Ownership - Chando was established in 2001 and has grown to become the second-largest domestic cosmetics brand in China, following Proya [1][12] - The Zheng siblings collectively control 87.82% of the voting rights in Chando, with Zheng Chunying holding 55% of the shares [2][12] - Zheng Chunying is recognized as the wealthiest individual in Liaoyang, with a net worth of 11 billion RMB, ranking 2448th on the 2025 Hurun Global Rich List [2] Group 2: IPO and Strategic Investments - Prior to its IPO filing, Chando raised over 700 million RMB by bringing in strategic investors, including L'Oréal and Himalaya International, which provided both capital and technical support [4][5] - The post-investment valuation of Chando is approximately 6.826 billion RMB [4] Group 3: Financial Performance - Chando's revenue has shown consistent growth, with total revenues of 42.92 billion RMB in 2022, 44.42 billion RMB in 2023, and 46.01 billion RMB in 2024 [16] - The skincare segment contributes approximately 90% of Chando's total revenue, with the main brand Chando generating 94.6% to 95.9% of total income during the reporting periods [12][14] - Despite revenue growth, net profit has fluctuated, with a significant drop of 37.09% in 2024 to 1.9 billion RMB [16] Group 4: Marketing and Sales Strategy - Chando has invested heavily in marketing, with total marketing expenses reaching 6.534 billion RMB over three and a half years, accounting for over 50% of total revenue during the reporting periods [17][18] - The company has shifted its sales strategy towards online channels, increasing online revenue from 59.7% in 2022 to 68.8% in 2025 [20][21] Group 5: Operational Insights - Chando operates three factories in China, maintaining a high capacity utilization rate of 95.7% and 82.5% for its Shanghai and Linzhi factories, respectively [23] - The company has not declared any dividends since its inception and has a cash-to-short-debt ratio of 10.53, indicating a strong liquidity position [25][26]

Market Overview - The cosmetics sector experienced a slight decline of 0.13% on December 26, with Qingsong Co. leading the drop [1] - The Shanghai Composite Index closed at 3963.68, up 0.1%, while the Shenzhen Component Index closed at 13603.89, up 0.54% [1] Individual Stock Performance - Marubi Biotechnology (603983) closed at 33.09, up 0.91% with a trading volume of 23,700 shares and a turnover of 78.26 million yuan [1] - Shanghai Jahwa (600315) closed at 23.17, up 0.83% with a trading volume of 32,000 shares and a turnover of 74.08 million yuan [1] - Furuida (600223) closed at 7.39, up 0.41% with a trading volume of 55,100 shares and a turnover of 40.71 million yuan [1] - Proya Cosmetics (603605) closed at 67.92, up 0.06% with a trading volume of 27,900 shares and a turnover of 20.06 million yuan [1] - Betaini (300957) closed at 40.48, down 0.59% with a trading volume of 37,100 shares and a turnover of 151 million yuan [1] - Other notable declines include Qingsong Co. (300132) down 1.57% and Jinsong New Materials (300849) down 1.55% [2] Capital Flow Analysis - The cosmetics sector saw a net outflow of 80.47 million yuan from institutional investors, while retail investors contributed a net inflow of 70.02 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Detailed Capital Flow for Selected Stocks - Furuida (600223) had a net inflow of 7.77 million yuan from institutional investors, but a net outflow of 4.35 million yuan from retail investors [3] - Huaye Fragrance (300886) saw a net inflow of 3.30 million yuan from institutional investors, while retail investors had a net outflow of 1.01 million yuan [3] - Marubi Biotechnology (603983) experienced a net inflow of 1.22 million yuan from institutional investors, with retail investors also seeing a net outflow [3] - Qingsong Co. (300132) had a significant net outflow of 1.57 million yuan from institutional investors [3]